Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
Trial ID or NCT#
NCT06345404
Status
RECRUITING
Purpose
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Official Title
A Phase 1, Randomized, Blinded, Placebo-controlled, Dose Escalation Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of ITK Inhibitor Soquelitinib in Participants With Moderate to Severe Atopic Dermatitis
Investigator(s)
Albert Sean Chiou, MD, MBA
Dermatologist,
Cutaneous oncology specialist
Clinical Associate Professor, Dermatology
Contact us to find out if this trial is right for you.
Contact
Liza Tom
650-900-4514
View on